WuXi XDC Cayman Valuation

Is L74 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of L74 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: L74 (€3.78) is trading below our estimate of fair value (€4.93)

Significantly Below Fair Value: L74 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for L74?

Key metric: As L74 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for L74. This is calculated by dividing L74's market cap by their current earnings.
What is L74's PE Ratio?
PE Ratio59.7x
EarningsCN¥594.55m
Market CapCN¥35.51b

Price to Earnings Ratio vs Peers

How does L74's PE Ratio compare to its peers?

The above table shows the PE ratio for L74 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.4x
1SXP SCHOTT Pharma KGaA
24.9x15.7%€3.7b
GXI Gerresheimer
21.2x21.8%€2.4b
SRT3 Sartorius
193.1x35.2%€13.5b
DMP Dermapharm Holding
22.5x17.0%€2.0b
L74 WuXi XDC Cayman
59.7x27.5%€37.8b

Price-To-Earnings vs Peers: L74 is good value based on its Price-To-Earnings Ratio (59.7x) compared to the peer average (65.4x).


Price to Earnings Ratio vs Industry

How does L74's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
L74 59.7xIndustry Avg. 37.5xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: L74 is expensive based on its Price-To-Earnings Ratio (59.7x) compared to the European Life Sciences industry average (37.5x).


Price to Earnings Ratio vs Fair Ratio

What is L74's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

L74 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio59.7x
Fair PE Ratio22.9x

Price-To-Earnings vs Fair Ratio: L74 is expensive based on its Price-To-Earnings Ratio (59.7x) compared to the estimated Fair Price-To-Earnings Ratio (22.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst L74 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.78
€3.95
+4.6%
20.3%€5.30€2.20n/a13
Dec ’25€3.24
€3.73
+15.0%
18.7%€5.15€2.19n/a13
Nov ’25€2.58
€3.62
+40.3%
20.0%€5.11€2.14n/a12
Oct ’25€2.62
€3.50
+33.5%
19.7%€5.01€2.07n/a12
Sep ’25€2.24
€3.46
+54.2%
19.5%€4.95€2.06n/a12
Aug ’25€2.04
€3.63
+78.2%
19.9%€4.81€2.13n/a12
Jul ’25€1.92
€3.69
+92.3%
19.8%€4.85€2.15n/a12
Jun ’25€1.68
€3.67
+118.5%
19.8%€4.82€2.12n/a12
May ’25€2.52
€3.70
+46.8%
20.7%€4.88€2.15n/a11
Apr ’25€2.04
€3.51
+71.9%
22.6%€4.87€2.14n/a11
Mar ’25€2.08
€4.80
+131.0%
6.4%€5.66€4.42n/a11
Feb ’25€2.40
€4.74
+97.5%
6.4%€5.58€4.35n/a11
Jan ’25€3.52
€4.59
+30.4%
11.5%€5.54€3.30n/a10

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:25
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi XDC Cayman Inc. is covered by 19 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited
Bo YuChina International Capital Corporation Limited